Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Literature DB >> 20065078

Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Adele K Fielding.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2010 PMID： 20065078 PMCID： PMC2805747 DOI： 10.3324/haematol.2009.015974

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

30 in total

1. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Authors: Barbara Wassmann; Heike Pfeifer; Nicola Goekbuget; Dietrich W Beelen; Joachim Beck; Matthias Stelljes; Martin Bornhäuser; Albrecht Reichle; Jolanta Perz; Rainer Haas; Arnold Ganser; Mathias Schmid; Lothar Kanz; Georg Lenz; Martin Kaufmann; Anja Binckebanck; Patrick Brück; Regina Reutzel; Harald Gschaidmeier; Stefan Schwartz; Dieter Hoelzer; Oliver G Ottmann
Journal: Blood Date: 2006-04-25 Impact factor: 22.113

2. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.

Authors: Masayuki Towatari; Masamitsu Yanada; Noriko Usui; Jin Takeuchi; Isamu Sugiura; Makoto Takeuchi; Fumiharu Yagasaki; Yasukazu Kawai; Shuichi Miyawaki; Shigeki Ohtake; Itsuro Jinnai; Keitaro Matsuo; Tomoki Naoe; Ryuzo Ohno
Journal: Blood Date: 2004-08-17 Impact factor: 22.113

3. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol.

Authors: Marco Vignetti; Paola Fazi; Giuseppe Cimino; Giovanni Martinelli; Francesco Di Raimondo; Felicetto Ferrara; Giovanna Meloni; Achille Ambrosetti; Giovanni Quarta; Livio Pagano; Giovanna Rege-Cambrin; Loredana Elia; Raffaello Bertieri; Luciana Annino; Robin Foà; Michele Baccarani; Franco Mandelli
Journal: Blood Date: 2007-01-09 Impact factor: 22.113

4. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Authors: Barbara Wassmann; Heike Pfeifer; Michael Stadler; Martin Bornhaüser; Gesine Bug; Urban J Scheuring; Patrick Brück; Matthias Stelljes; Rainer Schwerdtfeger; Nadezda Basara; Jolanta Perz; Donald Bunjes; Georg Ledderose; Rolf Mahlberg; Anja Binckebanck; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann
Journal: Blood Date: 2005-04-07 Impact factor: 22.113

5. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

Authors: Adrienne de Labarthe; Philippe Rousselot; Françoise Huguet-Rigal; Eric Delabesse; Francis Witz; Sébastien Maury; Delphine Réa; Jean-Michel Cayuela; Marie-Christine Vekemans; Oumedaly Reman; Agnès Buzyn; Arnaud Pigneux; Martine Escoffre; Yves Chalandon; Elizabeth MacIntyre; Véronique Lhéritier; Jean-Paul Vernant; Xavier Thomas; Norbert Ifrah; Hervé Dombret
Journal: Blood Date: 2006-10-24 Impact factor: 22.113

6. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Authors: Heike Pfeifer; Barbara Wassmann; Anna Pavlova; Lydia Wunderle; Johannes Oldenburg; Anja Binckebanck; Thoralf Lange; Andreas Hochhaus; Silvia Wystub; Patrick Brück; Dieter Hoelzer; Oliver G Ottmann
Journal: Blood Date: 2007-04-03 Impact factor: 22.113

7. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

Authors: Jacob M Rowe; Georgina Buck; Alan K Burnett; Raj Chopra; Peter H Wiernik; Susan M Richards; Hillard M Lazarus; Ian M Franklin; Mark R Litzow; Niculae Ciobanu; H Grant Prentice; Jill Durrant; Martin S Tallman; Anthony H Goldstone
Journal: Blood Date: 2005-08-16 Impact factor: 22.113

8. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.

Authors: R A Larson; R K Dodge; C P Burns; E J Lee; R M Stone; P Schulman; D Duggan; F R Davey; R E Sobol; S R Frankel
Journal: Blood Date: 1995-04-15 Impact factor: 22.113

9. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.

Authors: M Schrappe; M Aricò; J Harbott; A Biondi; M Zimmermann; V Conter; A Reiter; M G Valsecchi; H Gadner; G Basso; C R Bartram; F Lampert; H Riehm; G Masera
Journal: Blood Date: 1998-10-15 Impact factor: 22.113

Review 10. Philadelphia positive acute lymphoblastic leukaemia of childhood.

Authors: Louise K Jones; Vaskar Saha
Journal: Br J Haematol Date: 2005-08 Impact factor: 6.998

10 in total

1. Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood.

Authors: Hong Hoe Koo
Journal: Korean J Pediatr Date: 2011-03-31

2. Transient pancytopenia preceding adult acute lymphoblastic leukemia with chromosomal abnormalities including the Philadelphia chromosome: A case report and review of the literature.

Authors: Yun Liang; Luyin Ding; Xian Li; Weiqin Wang; Xiaohong Zhang
Journal: Oncol Lett Date: 2015-09-29 Impact factor: 2.967

3. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.

Authors: Ohad Benjamini; Theresa Liu Dumlao; Hagop Kantarjian; Susan O'Brien; Guillermo Garcia-Manero; Stefan Faderl; Jeffrey Jorgensen; Rajyalakshmi Luthra; Rebecca Garris; Deborah Thomas; Partow Kebriaei; Richard Champlin; Elias Jabbour; Jan Burger; Jorge Cortes; Farhad Ravandi
Journal: Am J Hematol Date: 2014-03 Impact factor: 10.047

4. Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR-ABL1 on the international reporting scale.

Authors: J T Brown; W Laosinchai-Wolf; J B Hedges; C D Watt; V M Van Deerlin; L Fletcher; S Branford; E Labourier
Journal: Blood Cancer J Date: 2011-03-25 Impact factor: 11.037

5. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.

Authors: Franck E Nicolini; Grzegorz W Basak; Dong-Wook Kim; Eduardo Olavarria; Javier Pinilla-Ibarz; Jane F Apperley; Timothy Hughes; Dietger Niederwieser; Michael J Mauro; Charles Chuah; Andreas Hochhaus; Giovanni Martinelli; Maral DerSarkissian; Mei Sheng Duh; Lisa J McGarry; Hagop M Kantarjian; Jorge E Cortes
Journal: Cancer Date: 2017-04-07 Impact factor: 6.860

6. Serological Evaluation of Anti-Toxoplasma gondii Antibodies in Patients with Acute Leukemia and Lymphoma through Chemotherapy.

Authors: Fatemeh Tabatabaie; Taher Elmi; Majid Khanmohammadi; Lame Akhlaghi; Mahmoud Mahami-Oskouei; Mehdi Arshadi
Journal: Iran J Parasitol Date: 2020 Apr-Jun Impact factor: 1.012

10. Preparation and Characterization of a Novel Swellable and Floating Gastroretentive Drug Delivery System (sfGRDDS) for Enhanced Oral Bioavailability of Nilotinib.

Authors: Hong-Liang Lin; Ling-Chun Chen; Wen-Ting Cheng; Wei-Jie Cheng; Hsiu-O Ho; Ming-Thau Sheu
Journal: Pharmaceutics Date: 2020-02-06 Impact factor: 6.321